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Increased Expression of HLA DR2 in Acquired Aplastic Anemia and its impact on
response to Immunosuppressive Therapy
M. Usman, S. N. Adil, T. Moatter, F. Bilwani, S. Arian, M. Khurshid
Department of Pathology, The Aga Khan University Hospital, Karachi.
Abstract
Objective: To study the frequency of HLA DR2 status of patients with aplastic anemia and their response to
immunosuppressive therapy at a tertiary care hospital.
Methods: Thirty eight consecutive patients of acquired aplastic anemia were evaluated with respect to demo-
graphic features, severity of HLA DR2 status and response outcome to immunosuppressive therapy.
Results: The mean age of the patients was 24.6 years + 16.4 with a male to female ratio of 2.8:1. Positivity of
HLA DR2 was markedly high in acquired aplastic anemia patients. Twenty four (65%) out of 38 patients as com-
pared to 45 (15%) of 300 healthy controls (p<0.0001) were positive for HLA DR2. Response to immunosuppres-
sive therapy, which included antilymphocyte globulin, cyclosporin and methylprednisolone, was available in six-
teen HLA DR2 positive patients and was found satisfactory in 12/16 (75%) patients.
Conclusion: HLA DR2 was significantly higher in patients with acquired aplastic anemia and favourable
response to immunosuppressive therapy was also associated with HLA DR2 positivity (JPMA 54:251;2004).
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Introduction
By definition aplastic anemia is described as pancy-
topenia with empty bone marrow in which the marrow is
replaced by fat cells. The etiology of acquired aplastic ane-
mia is largely unknown, however in one third of the patients
it has been associated with viruses, drugs and chemicals.1
The way in which these agents produce aplastic anemia is
unknown but it has been suggested that both stem cells and
microenvironmental factors play a part. Activated CD8+
lymphocytes may play a role in inducing the production of
gamma interferon, which lead to nitrous oxide synthesis in
stem cells causing apoptosis.2
It has been shown that many autoimmune disorders
are strongly associated with certain HLA DR phenotype.
Since acquired aplastic anemia has an immune etiology, and
it was noted that HLA DR2 phenotype is more common in
patients with aplastic anemia3, its expression has been sug-
gested to predict a response to anti lymphocyte globulin and
cyclosporin. When aplastic anemia patients were assessed
for response to cyclosporin; the response rate in patients
with HLA DR2 was significantly higher.4,5 Based on these
informations, we studied the frequency of HLA DR2 status
of patients with acquired apalstic anemia and their response
to immunosuppressive therapy.
Methods
This retrospective cross-sectional study was con-
ducted at the Aga Khan University Hospital on patients who
presented to the hematology outpatient or inpatient in the
hospital during the period of January 1993 to July 2001. The
medical record department of the hospital retrieved the
medical records of the patients and the data was recorded on
a preformed questionnaire. The demographic features
including age, sex, month and year of presentation were
noted along with severity of aplastic anemia. 
Patients with acquired aplastic anemia were diag-
nosed according to the International Study of Aplastic
Anemia Group.6 The severity was classified according to
the Camitta classification.7 Patients of Fanconi's anemia,
hypoplastic myelodysplastic syndrome and hypoplastic
acute lymphoblastic leukemia was excluded.   
Patients received immunosuppressive therapy which
consisted of injection anti lymphocyte globulins 10 mg/kg
daily for 5 days, injection methylprednisolone 2mg/ kg for
4 days and then gradual tapering off with oral steroids with-
in two weeks and cap. cyclosporin 10 mg /kg per OS daily
for six months. However, the dose of cyclosporin was titrat-
ed according to the serum level.   Patients who received
immunosuppressive therapy were assessed for response at 6
months.
Response criteria was defined as follows:
a) Complete response: Transfusion independence to both
packed red cell and platelets.
b) Partial response: Transfusion independence to one com-
ponent, either packed red cells or platelets.
c) No response: Transfusion dependence to both packed
red cells and platelets.
Methodology for HLA DR analysis
HLA DR analysis by polymerase chain reaction-sequence
specific primer
We applied low-resolution HLA typing results for
class II using sequence specific primer, a form of poly-
merase chain reaction (One Lambda, USA) The final PCR
product was visualized on a 1.5% agarose gel and the pres-
ence or absence of appropriately sized bands was assessed.
The results of typing were then converted to already estab-
lished HLA  phenotypic equivalents and HLA DRB 1*15
and DRB1*16 were analyzed as HLA DR2. The control
group (n=300) comprised of healthy individuals of
Pakistani population belonging to all ethnic groups, the
majority being donors for bone marrow and renal transplan-
tation.
Statistical data was analyzed using statistical pack-
age SPSS for Window's version 10.0. Chi-square test was
used to analyze p value. Statistical differences between var-
ious groups and a p value of <0.05 was consistent as signif-
icant.
Results
Thirty eight consecutive patients meeting the criteria
for the diagnosis of aplastic anemia were evaluated for HLA
typing. Further characteristics of these patients are given in
Table. The male to female ratio was 2.8:1. The mean age
was 24.6 years and ranged between 4 years and 70 years.
Five patients were less than 14 years of age.
Table. Characteristics of patients.
Total number of patients 38
Male to female ratio 2.8:1
Mean age (years) 24.6±16.4
Median age (years) 21 (range 4-70)
HLA DR2 positive 25 (65.7%)
HLA DR2 negative 13 (34.2%)
Severity of aplastic anemia
Severe 27
Very severe 11
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Twenty five (65.7%) of 38 patients were HLA DR2
positive. The frequency of HLA DR2 positivity in the con-
trol group (n=300) was 45 (15%) indicating higher frequen-
cy of HLA DR2 in patients with aplastic anemia
(p<0.0001).
Out of the total thirty eight patients, the response to
immunosuppressive therapy was evaluable in nineteen
patients. Sixteen and three patients belonged to HLA DR2
positive and negative groups respectively. Out of the sixteen
HLA DR2 positive patients, thirteen had severe aplastic
anemia whereas the other three belonged to very severe
group. Among the three HLA DR2 negative patients, two
were severely aplastic and the remaining one patient was
suffering from very severe aplasia. All of them had received
anti lymphocyte globulin, steroids and cyclosporin as
described above.     
The response rate was 12/16 (75%) evaluated at six
months in HLA DR2 positive patients. Eleven patients had
complete response whereas one had partial response. Ten of
the thirteen severely aplastic and two of the three very
severely aplastic patients  responded to immunosuppressive
therapy respectively. 
In HLA DR2 negative group, two out of three
responded to immunosuppressive therapy.
Discussion
Keeping in view the pathogenesis of acquired aplas-
tic anemia, there is little doubt that the bone marrow stem
cells are destroyed by autoimmune process2, which is also
supported by the evidence of response to immunosuppres-
sive therapy.8 Genetic susceptibility and association of HLA
types with certain autoimmune diseases has been reported.9
Increase in frequency of HLA DR2 expression was noted in
patients with aplastic anemia.3,4,10 The expression of HLA
DR2 varies significantly in different ethnic groups. It was
reported as 25.3% for North American Caucasians
(n=1145), 14.8% for Hispanics of Mexican origin (n=88),
33.9% for American Blacks (n=168), 18.3% for Orientals
(n=536), 17.9% for Italy, 26.5% for Germany and 21.2% for
France.4,11
Those patients who have been diagnosed as a case of
acquired aplastic anemia, the frequency of HLA DR2 posi-
tivity was found as 31/75 (41.3%), 23/44 (44.2%) and
104/242 (43%)3,4,10 in various studies. Similarly, in this
study, a significantly higher expression of HLA DR2 when
compared to unrelated healthy controls (P=0.0001). 
HLA DR2 status of the aplastic anemia patients have
been examined for the ability to predict a clinical response
to immunosuppressive therapy, however no definitive state-
ment could be made regarding the predictive value of HLA
DR2 positive status in predicting the outcome. Conflicting
results have been reported so far and it was found to be pre-
dictive for immunosuppressive therapy in some studies
when comparing the HLA DR2 positive and negative group
as reported by Osman et al4 73.3% versus 30%, Shinji et al5
71% versus 35% and Jaroslaw et al10 34% versus 50%.
Similarly response rates to immunosuppressive were not
significantly different in HLA DR2 positive and negative
patients in other studies.3
In our study, we only focused on the response of
combination of immunosuppressive in HLA DR2 positive
subjects and we found that HLA DR2 positivity is signifi-
cantly associated with response to immunosuppressive ther-
apy. However no definitive statement could be made regard-
ing the predictive value of HLA DR2 positive status in pre-
dicting the outcome in our study because of smaller number
of patients in HLA DR2 negative group.
It is now accepted that more than 50% of patients
with aplastic anemia have an immunological basis of the
disease and it is postulated that the autoreactive T cells that
escape negative selection are normally kept under control
by largely unidentified regulatory mechanisms. And when
these mechanisms fail, the products of certain HLA mole-
cules with particular peptides can activate self-reactive T
cells.12 These particular groups of patients who are HLA
DR2 positive showed an excellent response to combination
immunosuppressive therapy and further support the
immunological basis of the disease.
At present, however, it is difficult to decide regard-
ing the use of immunosuppressive versus transplantation in
aplastic anemia patients solely on the criterion of HLA sta-
tus because a substantial proportion of HLA DR2 negative
patients also responded to immunosuppressive therapy sug-
gests some other mechanisms also play their role in the
pathogenesis of aplastic anemia.
References
1. Young NS. Aplastic anemia. Lancet, 1995; 346: 228-232.
2. Young NS, Maciejenski J. The pathophysiology of acquired aplastic anemia.
N Engl J Med 1997;336:1365-72.
3. Nimer SD, Ireland P, Meshkinpour A, et al. An increased HLA DR2 frequen-
cy is seen in aplastic anemia patients. Blood 1994;84:923-7.
4. Osman Ihan, Beksac M, Arslan O. HLA DR2: a predictive marker in response
to cyclosporine therapy in aplastic anemia. Int J Hematol 1997 66:291-5.
5. Shinji N, Hideyuki T. Identification of a specific HLA class II haplotype
strongly associated with susceptibility to cyclosporine-dependent aplastic
anemia. Blood 1994;84:4257-61.
6. Camitta BM, Thomas ED, Nathan DG. A prospective study of androgens and
bone marrow transplantation for treatment of severe aplastic anemia. Blood
1979;53:504.
7. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation ver-
sus immunosuppression for the treatment of severe aplastic anemia. A report
of European Bone Marrow Transplant severe aplastic anemia working party.
Br J Haematol 1988;70:177.
8. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia.
Blood 1995;85:3367-77.
9. Jan K, Akie S. The HLA system: advances in Immunology. Review articles.
N Engl J Med 2000;343:782. 
10. Maciejewski JP, Follmann D, Nakamura R, et al. increased frequency of
HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the
PNH/aplastic anemia syndrome. Blood 2001;98:3513-19.
11. Ihan O, Beksac M, Koc H. HLA DR frequency in Turkish aplastic anemia
patients and the impact of HLA DR2 positivity in response rate in patients
receiving immunosuppressive therapy. Blood 1995;86:2055.
Vol. 54, No. 5, May 2004 254
